ARCHIVES

Executive Committee, Board of Scientific Advisors concur.

This article is from The Cancer Letter archive.

Vol. 30 No. 01 | January 2, 2004

Download PDF Visit The Full Archive

Related Articles

Vanderbilt Recruits Sosman To Lead Tumor Immunology.

January 18, 2002

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

July 31, 2009

NCI Asks $955 Million In ’78; HEW Says $799 Will Be Enough

August 20, 1976

CPRIT Awards $107.2 Million Round of Grants

September 5, 2014

Radium 223 Dichloride Reduces Death Risk By 30 Percent in Castration-Resistant Disease

August 30, 2013

Phase II Trial of BIND-014 Shows Anti-Tumor Activity in Q3W Arm

November 28, 2014